If you are not happy with the results below please do another search
Janssen, a pharmaceutical company owned by Johnson and Johnson, and a Russian biopharmaceutical company Nanolek have announced the localization of manufacturing of Darzalex®(daratumumab) in Russia, which is used in treatment of multiple myeloma. The battle against malignant hematologic diseases has been a strategic direction that Janssen had been working towards for many years now. Our…
Residents of the MSU research park developed a unique treatment for battling sepsis. It has successfully passed all clinical trials and is soon expected to be available for use in hospitals. The new treatment is based on polymer sorbents derived for the first time. The press office of the university reported that scientists have developed…
Results of a study by INMARK® suggest that early administration of antifibrosis therapy allows to slow down the progression of idiopathic pulmonary fibrosis. Scientific journal The Lancet Respiratory Medicine published the results of a randomized double-blinded study by INMARK®, which validated the effectiveness of Vargatef (nintedanib) versus placebo in patients with idiopathic pulmonary fibrosis (IPF)…
Takeda Russia announced the launch of two new indications of Adsetris® on the Russian market: 1) the treatment of previously untreated patients with classical CD30 + Hodgkin’s lymphoma stage IV in combination with doxorubicin, vinblastine and dacarbazine; 2) the treatment of patients with CD30 + T-cell lymphoma of the skin after at least one line…
About 3 million Russians suffer from a disease that is considered incurable – hepatitis C. Despite the fact that over the past few years, the incidence in the country has decreased, about 15 thousand people die from the effects of chronic hepatitis C every year. The main danger of the disease is in its asymptomatic…
Chinese scientists have begun the second phase of clinical trials of the drug for the treatment of an autoimmune disease – systemic lupus erythematous. The new patent-protected drug SM934, which is a water-soluble artemisinin derivative, was developed by researchers at the Shanghai Institute of Pharmacology at the Academy of Sciences of China ANC. The first stage of…